Gentamicin Dosing Calculator
Calculate extended-interval gentamicin doses from weight and renal function. Enter values for instant results with step-by-step formulas.
Formula
Dose = DosePerKg x Dosing Weight; CrCl = ((140 - Age) x Weight) / (72 x SCr); Cmax = Dose / Vd
The dose is calculated using the dosing weight (IBW or adjusted BW) multiplied by the per-kilogram dose factor. Creatinine clearance is estimated via Cockcroft-Gault equation using dosing weight. Peak concentration is estimated by dividing the dose by the volume of distribution (0.25 L/kg). The elimination rate constant and half-life determine the appropriate dosing interval.
Worked Examples
Example 1: Extended-Interval Gentamicin for Pyelonephritis
Problem: A 65-year-old male, 80 kg, 175 cm tall, serum creatinine 1.2 mg/dL. Calculate extended-interval gentamicin dosing at 7 mg/kg.
Solution: IBW (male) = 50 + 2.3 x (68.9 - 60) = 50 + 20.5 = 70.5 kg\nActual (80) < 120% IBW (84.6), so use IBW: 70.5 kg\nCrCl = ((140-65) x 70.5) / (72 x 1.2) = 5,287.5 / 86.4 = 61.2 mL/min\nDose = 7 x 70.5 = 493.5, round to 490 mg\nVd = 0.25 x 70.5 = 17.6 L\nCmax = 490 / 17.6 = 27.8 mcg/mL\nke = 0.00293 x 61.2 + 0.014 = 0.193\nCrCl > 60, recommend q24h interval
Result: Dose: 490 mg IV q24h | Estimated peak: 27.8 mcg/mL | CrCl: 61.2 mL/min
Example 2: Obese Patient Dose Adjustment
Problem: A 45-year-old female, 110 kg, 160 cm tall, serum creatinine 0.8 mg/dL. Calculate gentamicin dose using adjusted body weight.
Solution: IBW (female) = 45.5 + 2.3 x (63.0 - 60) = 45.5 + 6.9 = 52.4 kg\nActual (110) > 120% IBW (62.9), use adjusted weight\nAdjBW = 52.4 + 0.4 x (110 - 52.4) = 52.4 + 23.0 = 75.4 kg\nCrCl = ((140-45) x 75.4) / (72 x 0.8) x 0.85 = 96.6 mL/min\nDose = 7 x 75.4 = 527.8, round to 530 mg\nVd = 0.25 x 75.4 = 18.9 L\nCmax = 530 / 18.9 = 28.0 mcg/mL
Result: Dose: 530 mg IV q24h | Adjusted BW: 75.4 kg | CrCl: 96.6 mL/min
Frequently Asked Questions
What is extended-interval aminoglycoside dosing?
Extended-interval dosing, also called once-daily or high-dose aminoglycoside dosing, administers a larger dose of gentamicin (5 to 7 mg/kg) at extended intervals of 24 to 48 hours rather than the traditional approach of smaller doses every 8 hours. This method exploits the concentration-dependent killing properties of aminoglycosides, where higher peak concentrations produce more rapid and complete bacterial killing. Additionally, the extended drug-free interval allows for washout from renal tubular cells, potentially reducing nephrotoxicity. The post-antibiotic effect of aminoglycosides, where bacterial suppression continues even after drug levels fall below the MIC, supports this dosing strategy. Multiple clinical trials have demonstrated equivalent or superior efficacy with reduced nephrotoxicity compared to traditional dosing.
How is the dosing weight determined for gentamicin?
Gentamicin dosing weight selection depends on the relationship between actual body weight and ideal body weight. Ideal body weight is calculated using the Devine formula, which uses height and sex. For patients whose actual weight is within 120 percent of their ideal body weight, the ideal body weight is used for dosing. For patients exceeding 120 percent of ideal body weight (obese patients), an adjusted body weight is calculated as ideal body weight plus 0.4 times the difference between actual and ideal weight. This adjustment accounts for the fact that aminoglycosides distribute into lean tissue and some, but not all, of the excess adipose tissue. Using actual body weight in obese patients would result in excessive dosing and increased toxicity risk.
What are the therapeutic peak and trough targets for gentamicin?
For extended-interval dosing, the target peak concentration is typically 15 to 25 mcg/mL, which maximizes concentration-dependent killing, while the trough should be undetectable or below 1 mcg/mL to minimize nephrotoxicity. For traditional dosing at 1 to 2 mg/kg every 8 hours, the target peak is 6 to 10 mcg/mL for serious infections and the trough should be below 2 mcg/mL. In certain infections like endocarditis synergy dosing, lower peaks of 3 to 4 mcg/mL are targeted. The Hartford nomogram is commonly used for extended-interval monitoring, where a single level drawn at a specific time after the dose determines the appropriate dosing interval based on a published nomogram.
How does renal function affect gentamicin dosing intervals?
Renal function is the primary determinant of gentamicin elimination and therefore directly determines the dosing interval. Patients with a creatinine clearance above 60 mL/min can receive extended-interval doses every 24 hours. Moderate renal impairment with creatinine clearance of 40 to 59 mL/min typically requires 36-hour intervals. Creatinine clearance of 20 to 39 mL/min warrants 48-hour intervals. Patients with creatinine clearance below 20 mL/min generally should not receive extended-interval dosing and may be better served with traditional dosing guided by individualized pharmacokinetic monitoring. Serum creatinine should be monitored daily during aminoglycoside therapy because the drug itself can cause nephrotoxicity, creating a dangerous feedback loop of declining renal function and drug accumulation.
How do gentamicin levels relate to ototoxicity risk?
Aminoglycoside ototoxicity affects both vestibular and cochlear function and may be irreversible, unlike nephrotoxicity which is usually reversible upon drug discontinuation. The mechanism involves destruction of sensory hair cells in the inner ear, with gentamicin preferentially causing vestibular toxicity while amikacin and tobramycin are more cochleotoxic. Risk factors include cumulative dose exposure, duration of therapy exceeding 14 days, concurrent use of loop diuretics, pre-existing hearing loss, and genetic susceptibility particularly the mitochondrial A1555G mutation. Monitoring should include baseline and serial audiometry when feasible, and patients should be asked about symptoms of dizziness, vertigo, tinnitus, and hearing changes throughout therapy. The estimated incidence ranges from 2 to 15 percent depending on the monitoring methods used.
When should traditional multiple-daily-dose gentamicin be used instead?
Traditional multiple-daily-dose gentamicin should be used in several clinical scenarios where extended-interval dosing has not been adequately validated or is contraindicated. These include bacterial endocarditis where synergistic dosing at 1 mg/kg every 8 hours is the standard protocol, pregnancy due to altered pharmacokinetics and insufficient safety data, significant burn patients with altered volume of distribution and renal clearance, patients with large-volume ascites who have unpredictable drug distribution, cystic fibrosis patients who have increased clearance, and patients with creatinine clearance below 20 mL/min where drug accumulation is difficult to predict. Neonatal dosing also follows different protocols based on gestational age and postnatal age.